Shots:
Abpro to receive ~$1.75B incl. an equity investment, development, and commercial milestones, and profit sharing globally
Celltrion will be responsible for the development of ABP 102 upon the completion of in vitro studies by Abpro and also gets the commercialization rights globally
The companies will combine Abpro’s Diversimmune and Multimab platform with Celltrion’s expertise in biology drug development globally to advance ABP 102 for the treatment of HER2+ breast, gastric, and pancreatic cancer. Additionally, Abpro’s ABP 102 showed the preliminary results of better efficacy and less toxicity over other therapies for the same indication
Ref: Businesswire | Image: Celltrion
